2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Abstract Number: 2174

Natural History of Sjögren’s Syndrome Phenotypic Features in the Sjögren’s International Collaborative Clinical Alliance Registry
Abstract Number: 149

Natural Language Processing in the Evaluation of Gout Quality Indicators
Abstract Number: 1184

Negative Association Between Testosterone Levels and Risk of Future Rheumatoid Factor Negative Rheumatoid Arthritis in Men
Abstract Number: 784

Neutralization of Plasminogen Activator Inhibitor-1 Resolves Skin Fibrosis and Vascular Injury in a Murine Model of Human Scleroderma
Abstract Number: 1699

Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry
Abstract Number: 2502

Neutrophil Extracellular Trap-Associated Protein Activation of the Inflammasome Is Enhanced in Lupus M1 Macrophages
Abstract Number: 2391

New Disease Manifestations After Diagnosis in Six Types of Vasculitis
Abstract Number: 973

New Genetic Risk Loci for the Radiographic Severity of Rheumatoid Arthritis
Abstract Number: 1627

New Insights Into the Presentation and the Management of Hepatitis B Reactivation in Patients with Autoimmune Diseases and Inflammatory Arthritis
Abstract Number: 1704

New Threshold Values for Spinal Mobility Measures Based On a Large Nationally Representative Sample of U.S. Adults Ages 20-69 Years
Abstract Number: 2083

New Treatment Approach of Rheumatoid Arthritis Based On Inhibition of Cyclin Dependent Kinase-9
Abstract Number: 308

Next-Generation Sequencing of Urinary Microrna in Human Lupus Nephritis
Abstract Number: 1599

NF-Kb Inducing Kinase (NIK) Is a Key Regulator of Inflammation-Induced Angiogenesis
Abstract Number: 589

NGF and Trka: A Novel Therapeutic Target in Chronic Inflammation
Abstract Number: 1191

Nicotinamide Adenine Dinucleotide Phosphate Oxidase Mediated Angiogenesis and Inflammation in the Arthritic Joint
Abstract Number: 694

Nilotinib (Tasigna™) in the Treatment of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial
Abstract Number: 190

NLRP3 Gene Analysis for Patients with Schnitzler’s Syndrome
Abstract Number: 2092

No Significant Effect of Hepatitis B Virus Infection On Disease Activity, Synovitis or Joint Destruction in Rheumatoid Arthritis
Abstract Number: 344

Non Classical Monocytes Are Required for Initiation Phase While Macrophages Are Necessary for the Resolution Phase in the K/BxN Murine of Inflammatory Arthritis
Abstract Number: 1381

Non-Radiographic Spondyloarthritis Has Greater Work Instability Than Other Spondyloarthritis Subtypes in a National Database
Abstract Number: 655

Non-White Race, Younger Age, and Use of Primary and Gynecologic Care Are Associated with Higher Rates of Cervical Cancer Screening in Systemic Lupus Erythematosus Patients At a Public Hospital
Abstract Number: 1138

Nonpharmacologic and Pharmacologic Therapy Utilization by Primary Care Providers for Hand Osteoarthritis-Comparative Review by Electronic Health Record Data Mining and in-Home Visit Verification
Abstract Number: 1790

Notch Promotes Matrix Metalloproteinase 13 Expression by Inducing Interleukin-6 in Primary Murine Chondrocytes
Abstract Number: 2579

Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Abstract Number: 2419

Novel Candidate Genes for Structural Foot Disorders: A Genome-Wide Association Study in an Older Caucasian Population
Abstract Number: 342

Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model
Abstract Number: 2678

Novel Nuclear Export Inhibitors Deplete Autoreactive Plasma Cells and Protect Mice with Lupus-Like Disease From Nephritis
Abstract Number: 33

Novel Targets for Blocking Osteoclast-Mediated Resorption in Inflammatory Disorders
Abstract Number: 2275

NR1H3 (LXR alpha) Gene Polymorphisms Are Associated with Systemic Lupus Erythematosus in Koreans
Abstract Number: 903

NR4A1 Mediates Anti-Inflammatory Effects of Apoptotic Cells
Abstract Number: 213

Nsaids Suppress the Inflammatory Reaction Related to Muscle Soreness but May Delay Recovery
Abstract Number: 533

NT-Probnp and Inflammation in Active Ankylosing Spondylitis Receiving TNF Blockers: Is There a Link?
Abstract Number: 893

Nuclear Factor-κB Activation by Type II Collagen Peptide in Osteoarthritic Chondrocytes: Its Inhibition by Hyaluronan Via CD44
Abstract Number: 898

Nuclear Receptor Related 1 Induces Synovial Hyperplasia Via Transcriptional Regulation of Novel Target Genes
Abstract Number: 1449

Numbers of Splenic Long-Lived Plasma Cells in Autoimmune and Pre-Autoimmune Lupus Mice Are Linked to a Hyper-Responsive Variant of the Thrombopoietin Receptor and Enhanced Megakaryopoiesis

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].